Is Alnylam Pharmaceuticals Inc (ALNY) a risky stock?
As of July 21, 2026, Clavix grades Alnylam Pharmaceuticals Inc (ALNY) B- for risk, a composite score of 68 out of 100 on an A+ to F scale, which puts ALNY in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ALNY's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ALNY scores on each, as of July 21, 2026.
What's moving ALNY's risk right now
Company-specific signals Clavix flags behind ALNY's current grade, drawn from recent news and filings as of July 21, 2026.
Morgan Stanley raised its price target while BofA trimmed its ALNY target to $410, about a 10.9% cut, though BofA kept its buy rating. The split signals tempered near-term valuation but continued confidence in long-term growth, helped by a rival's TTR trial failure.
Alnylam is set to report Q2 2026 financial results and hold a conference call to discuss them. BofA says the print will likely shape rating expectations and the 2026 revenue trajectory, which could drive near-term stock swings.
At AAIC 2026, Alnylam presented neuroscience programs targeting conditions like Alzheimer's, expanding beyond its core rare disease franchise. The pipeline move could open a much larger patient market, though an ARIA safety signal was flagged.
What a B- grade means
On the Clavix A+ to F scale, ALNY's composite of 68 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ALNY or any security. Grades are risk indicators, not predictions of return. Data may be delayed.